BERTANI, LORENZO Statistiche
BERTANI, LORENZO
DIPARTIMENTO DI RICERCA TRASLAZIONALE E DELLE NUOVE TECNOLOGIE IN MEDICINA E CHIRURGIA
A low-FODMAP diet for irritable bowel syndrome: Some answers to the doubts from a long-term follow-up
2020-01-01 Bellini, M.; Tonarelli, S.; Barracca, F.; Morganti, R.; Pancetti, A.; Bertani, L.; Bortoli, N.; Costa, F.; Mosca, M.; Marchi, S.; Rossi, A.
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study
2021-01-01 Barberio, B.; Cingolani, L.; Canova, C.; Barbieri, G.; Sablich, R.; Urbano, M. T.; Bertani, L.; Costa, F.; Bodini, G.; Demarzo, M. G.; Ferronato, A.; Buda, A.; Melatti, P.; Massimi, D.; Savarino, E. V.; Zingone, F.
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care
2020-01-01 Saibeni, S.; Scucchi, L.; Dragoni, G.; Bezzio, C.; Miranda, A.; Ribaldone, D. G.; Bertani, A.; Bossa, F.; Allocca, M.; Buda, A.; Mocci, G.; Soriano, A.; Mazzuoli, S.; Bertani, L.; Baccini, F.; Loddo, E.; Privitera, A. C.; Sartini, A.; Viscido, A.; Grossi, L.; Casini, V.; Gerardi, V.; Ascolani, M.; Ruscio, M. D.; Casella, G.; Savarino, E.; Stradella, D.; Pumpo, R.; Cortelezzi, C. C.; Daperno, M.; Ciardo, V.; Nardone, O. M.; Caprioli, F.; Vitale, G.; Cappello, M.; Comberlato, M.; Alvisi, P.; Festa, S.; Campigotto, M.; Bodini, G.; Balestrieri, P.; Viola, A.; Pugliese, D.; Armuzzi, A.; Fantini, M. C.; Fiorino, G.
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
2021-01-01 Cingolani, L.; Barberio, B.; Zingone, F.; Ferronato, A.; Bertani, L.; Costa, F.; Bodini, G.; Demarzo, M. G.; Melatti, P.; Gubbiotti, A.; Massimi, D.; Casadei, C.; D'Inca, R.; Savarino, E. V.
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)
2021-01-01 Bartolini, C; Ferraro, S; Convertino, I; Bertani, L; Giometto, S; Costa, F; Blandizzi, C; Lucenteforte, E; Gini, R; Tuccori, M
Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis
2022-01-01 D'Antongiovanni, Vanessa; Pellegrini, Carolina; Benvenuti, Laura; Fornai, Matteo; Di Salvo, Clelia; Natale, Gianfranco; Ryskalin, Larisa; Bertani, Lorenzo; Lucarini, Elena; Di Cesare Mannelli, Lorenzo; Ghelardini, Carla; Nemeth, Zoltan H; Haskó, György; Antonioli, Luca
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications
2019-01-01 Savarino, Edoardo; Bertani, Lorenzo; Ceccarelli, Linda; Bodini, Giorgia; Zingone, Fabiana; Buda, Andrea; Facchin, Sonia; Lorenzon, Greta; Marchi, Santino; Marabotto, Elisa; De Bortoli, Nicola; Savarino, Vincenzo; Costa, Francesco; Blandizzi, Corrado
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications
2019-01-01 Savarino, E.; Bertani, L.; Ceccarelli, L.; Bodini, G.; Zingone, F.; Buda, A.; Facchin, S.; Lorenzon, G.; Marchi, S.; Marabotto, E.; De Bortoli, N.; Savarino, V.; Costa, F.; Blandizzi, C.
Are PPI responder patients always confirmed as GERD patients? A MII-PH study.
2012-01-01 DE BORTOLI, Nicola; Martinucci, I.; Savarino, E.; Bolognesi, V.; Ussia, V.; Bertani, L.; Racale, C.; Frattino, A.; Bellini, M.; Marchi, Santino
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients
2020-01-01 Bertani, L.; Baglietto, L.; Antonioli, L.; Fornai, M.; Tapete, G.; Albano, E.; Ceccarelli, L.; Mumolo, M. G.; Pellegrini, C.; Lucenteforte, E.; de Bortoli, N.; Bellini, M.; Marchi, S.; Blandizzi, C.; Costa, F.
Barrett's esophagus in 2016: From pathophysiology to treatment
2016-01-01 Martinucci, Irene; DE BORTOLI, Nicola; Russo, Salvatore; Bertani, Lorenzo; Furnari, Manuele; Mokrowiecka, Anna; Malecka Panas, Ewa; Savarino, Vincenzo; Savarino, Edoardo; Marchi, Santino
Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis
2019-01-01 Bertani, L.; Bodini, G.; Mumolo, M. G.; de Bortoli, N.; Ceccarelli, L.; Frazzoni, L.; Tapete, G.; Albano, E.; Plaz Torres, M. C.; Bellini, M.; Savarino, E.; Savarino, V.; Marchi, S.; Costa, F.; Bellini, Massimo
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy
2021-01-01 Ferraro, S; Bartolini, C; Convertino, I; Bertani, L; Giometto, S; Cappello, E; Valdiserra, G; Tillati, S; Blandizzi, C; Lucenteforte, E; Costa, F; Gini, R; Tuccori, M
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
2019-01-01 Guidi, L.; Pugliese, D.; Tonucci, T. P.; Bertani, L.; Costa, F.; Privitera, G.; Tolusso, B.; Di Mario, C.; Albano, E.; Tapete, G.; Gremese, E.; Papa, A.; Gasbarrini, A.; Rapaccini, G. L.; Armuzzi, A.
Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' reply
2020-01-01 Bertani, L.; Pugliese, D.; Trico, D.; Costa, F.; Blandizzi, C.
Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab—authors' reply
2020-01-01 Bertani, L.; Fornai, M.; Antonioli, L.; Blandizzi, C.
Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issue
2022-01-01 Bertani, Lorenzo; Tricò, Domenico
Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial
2018-01-01 Cremon, Cesare; Guglielmetti, Simone; Gargari, Giorgio; Taverniti, Valentina; Castellazzi, Anna Maria; Valsecchi, Chiara; Tagliacarne, Carlotta; Fiore, Walter; Bellini, Massimo; Bertani, Lorenzo; Gambaccini, Dario; Cicala, Michele; Germanà, Bastianello; Vecchi, Maurizio; Pagano, Isabella; Barbaro, Maria Raffaella; Bellacosa, Lara; Stanghellini, Vincenzo; Barbara, Giovanni
Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry
2022-01-01 Tapete, Gherardo; Bertani, Lorenzo; Pieraccini, Alberto; Lynch, Erica Nicola; Giannotta, Martina; Morganti, Riccardo; Biviano, Ivano; Naldini, Sara; Mumolo, Maria Gloria; De Nigris, Francesca; Calella, Francesca; Bagnoli, Siro; Minciotti, Moira; Maltinti, Simona; Rentini, Silvia; Ceccarelli, Linda; Lionetti, Paolo; Milla, Monica; Costa, Francesco
Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults
2021-01-01 Visaggi, P.; Savarino, E.; Sciume, G.; Chio, T. D.; Bronzini, F.; Tolone, S.; Frazzoni, M.; Pugno, C.; Ghisa, M.; Bertani, L.; Bellini, M.; Savarino, V.; Peroni, D.; Marchi, S.; de Bortoli, N.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A low-FODMAP diet for irritable bowel syndrome: Some answers to the doubts from a long-term follow-up | 1-gen-2020 | Bellini, M.; Tonarelli, S.; Barracca, F.; Morganti, R.; Pancetti, A.; Bertani, L.; Bortoli, N.; Costa, F.; Mosca, M.; Marchi, S.; Rossi, A. | |
| A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study | 1-gen-2021 | Barberio, B.; Cingolani, L.; Canova, C.; Barbieri, G.; Sablich, R.; Urbano, M. T.; Bertani, L.; Costa, F.; Bodini, G.; Demarzo, M. G.; Ferronato, A.; Buda, A.; Melatti, P.; Massimi, D.; Savarino, E. V.; Zingone, F. | |
| Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care | 1-gen-2020 | Saibeni, S.; Scucchi, L.; Dragoni, G.; Bezzio, C.; Miranda, A.; Ribaldone, D. G.; Bertani, A.; Bossa, F.; Allocca, M.; Buda, A.; Mocci, G.; Soriano, A.; Mazzuoli, S.; Bertani, L.; Baccini, F.; Loddo, E.; Privitera, A. C.; Sartini, A.; Viscido, A.; Grossi, L.; Casini, V.; Gerardi, V.; Ascolani, M.; Ruscio, M. D.; Casella, G.; Savarino, E.; Stradella, D.; Pumpo, R.; Cortelezzi, C. C.; Daperno, M.; Ciardo, V.; Nardone, O. M.; Caprioli, F.; Vitale, G.; Cappello, M.; Comberlato, M.; Alvisi, P.; Festa, S.; Campigotto, M.; Bodini, G.; Balestrieri, P.; Viola, A.; Pugliese, D.; Armuzzi, A.; Fantini, M. C.; Fiorino, G. | |
| Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator | 1-gen-2021 | Cingolani, L.; Barberio, B.; Zingone, F.; Ferronato, A.; Bertani, L.; Costa, F.; Bodini, G.; Demarzo, M. G.; Melatti, P.; Gubbiotti, A.; Massimi, D.; Casadei, C.; D'Inca, R.; Savarino, E. V. | |
| Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) | 1-gen-2021 | Bartolini, C; Ferraro, S; Convertino, I; Bertani, L; Giometto, S; Costa, F; Blandizzi, C; Lucenteforte, E; Gini, R; Tuccori, M | |
| Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis | 1-gen-2022 | D'Antongiovanni, Vanessa; Pellegrini, Carolina; Benvenuti, Laura; Fornai, Matteo; Di Salvo, Clelia; Natale, Gianfranco; Ryskalin, Larisa; Bertani, Lorenzo; Lucarini, Elena; Di Cesare Mannelli, Lorenzo; Ghelardini, Carla; Nemeth, Zoltan H; Haskó, György; Antonioli, Luca | |
| Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications | 1-gen-2019 | Savarino, Edoardo; Bertani, Lorenzo; Ceccarelli, Linda; Bodini, Giorgia; Zingone, Fabiana; Buda, Andrea; Facchin, Sonia; Lorenzon, Greta; Marchi, Santino; Marabotto, Elisa; De Bortoli, Nicola; Savarino, Vincenzo; Costa, Francesco; Blandizzi, Corrado | |
| Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications | 1-gen-2019 | Savarino, E.; Bertani, L.; Ceccarelli, L.; Bodini, G.; Zingone, F.; Buda, A.; Facchin, S.; Lorenzon, G.; Marchi, S.; Marabotto, E.; De Bortoli, N.; Savarino, V.; Costa, F.; Blandizzi, C. | |
| Are PPI responder patients always confirmed as GERD patients? A MII-PH study. | 1-gen-2012 | DE BORTOLI, Nicola; Martinucci, I.; Savarino, E.; Bolognesi, V.; Ussia, V.; Bertani, L.; Racale, C.; Frattino, A.; Bellini, M.; Marchi, Santino | |
| Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients | 1-gen-2020 | Bertani, L.; Baglietto, L.; Antonioli, L.; Fornai, M.; Tapete, G.; Albano, E.; Ceccarelli, L.; Mumolo, M. G.; Pellegrini, C.; Lucenteforte, E.; de Bortoli, N.; Bellini, M.; Marchi, S.; Blandizzi, C.; Costa, F. | |
| Barrett's esophagus in 2016: From pathophysiology to treatment | 1-gen-2016 | Martinucci, Irene; DE BORTOLI, Nicola; Russo, Salvatore; Bertani, Lorenzo; Furnari, Manuele; Mokrowiecka, Anna; Malecka Panas, Ewa; Savarino, Vincenzo; Savarino, Edoardo; Marchi, Santino | |
| Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis | 1-gen-2019 | Bertani, L.; Bodini, G.; Mumolo, M. G.; de Bortoli, N.; Ceccarelli, L.; Frazzoni, L.; Tapete, G.; Albano, E.; Plaz Torres, M. C.; Bellini, M.; Savarino, E.; Savarino, V.; Marchi, S.; Costa, F.; Bellini, Massimo | |
| Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy | 1-gen-2021 | Ferraro, S; Bartolini, C; Convertino, I; Bertani, L; Giometto, S; Cappello, E; Valdiserra, G; Tillati, S; Blandizzi, C; Lucenteforte, E; Costa, F; Gini, R; Tuccori, M | |
| Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease | 1-gen-2019 | Guidi, L.; Pugliese, D.; Tonucci, T. P.; Bertani, L.; Costa, F.; Privitera, G.; Tolusso, B.; Di Mario, C.; Albano, E.; Tapete, G.; Gremese, E.; Papa, A.; Gasbarrini, A.; Rapaccini, G. L.; Armuzzi, A. | |
| Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' reply | 1-gen-2020 | Bertani, L.; Pugliese, D.; Trico, D.; Costa, F.; Blandizzi, C. | |
| Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab—authors' reply | 1-gen-2020 | Bertani, L.; Fornai, M.; Antonioli, L.; Blandizzi, C. | |
| Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issue | 1-gen-2022 | Bertani, Lorenzo; Tricò, Domenico | |
| Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial | 1-gen-2018 | Cremon, Cesare; Guglielmetti, Simone; Gargari, Giorgio; Taverniti, Valentina; Castellazzi, Anna Maria; Valsecchi, Chiara; Tagliacarne, Carlotta; Fiore, Walter; Bellini, Massimo; Bertani, Lorenzo; Gambaccini, Dario; Cicala, Michele; Germanà, Bastianello; Vecchi, Maurizio; Pagano, Isabella; Barbaro, Maria Raffaella; Bellacosa, Lara; Stanghellini, Vincenzo; Barbara, Giovanni | |
| Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry | 1-gen-2022 | Tapete, Gherardo; Bertani, Lorenzo; Pieraccini, Alberto; Lynch, Erica Nicola; Giannotta, Martina; Morganti, Riccardo; Biviano, Ivano; Naldini, Sara; Mumolo, Maria Gloria; De Nigris, Francesca; Calella, Francesca; Bagnoli, Siro; Minciotti, Moira; Maltinti, Simona; Rentini, Silvia; Ceccarelli, Linda; Lionetti, Paolo; Milla, Monica; Costa, Francesco | |
| Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults | 1-gen-2021 | Visaggi, P.; Savarino, E.; Sciume, G.; Chio, T. D.; Bronzini, F.; Tolone, S.; Frazzoni, M.; Pugno, C.; Ghisa, M.; Bertani, L.; Bellini, M.; Savarino, V.; Peroni, D.; Marchi, S.; de Bortoli, N. |